Abstract: Provided herein are containerized liquid formulations comprising a plurality of agrochemicals. The formulations comprise a plurality of parallel liquid layers, wherein each layer is disposed within the container such that it is in contact with at least one adjacent layer at an interface. Also provided are methods of preparing, storing, shipping, and using the containerized liquid formulations.

Abstract: The present invention provides a method for treating various skin diseases by topically administering to a subject a composition formulated as a foamable composition which includes a corticosteroid, such as halobetasol. The composition may include a corticosteroid, ethyl alcohol, emulsifying wax, cetostearyl alcohol, polyoxyl 20 cetostearyl ether, water, benzoic acid and propellant.

Abstract: A personal care composition, comprising a soluble zinc polyphosphate complex made by combining ingredients comprising an organic zinc salt, a plurality of long chain polyphosphates having 6 or more phosphate polymer units, and an aqueous solvent; wherein the relative amount of organic zinc salt and long chain polyphosphates provides a phosphorus to zinc mole ratio of at least 6:1. Also, a method of using the composition for reducing at least one of perspiration or body odor.

Abstract: The presently claimed invention relates to methods of reducing the duration or severity of an inflammatory immune response. In embodiments, the method comprises administering poly (lactic acid) (PLA) particles, poly (glycolic acid) (PGA) particles, poly (lactic-co-glycolic acid) (PLGA) particles, or combinations thereof; wherein said particles are modified to contain one or more carboxyl groups on the particle's surface. In embodiments, the particles do not comprise therapeutically active ingredients.

Abstract: Provided is a method of enhancing toxicity of a glycolytic dependent compound towards a cell, tissue and/or organ e.g. a diseased cell, tissue and/or organ, the method comprises contacting Oxidized Regenerated Cellulose (ORC) and/or Oxidized Cellulose (OC); and a glycolytic dependent compound with the cell, tissue and/or organ. The ORC and/or OC; and the glycolytic dependent compound are contacted with the cell, tissue and/or organ in a non-blended form.

Abstract: Disclosed herein are microbial consortia and compositions including microbes for use in agricultural or biodegradation applications. In some embodiments, soil, plants, and/or plant parts (such as seeds, seedlings, shoots, roots, leaves, fruit, stems, or branches) are contacted with a disclosed microbial consortia or composition including microbes. The microbial consortia or microbe-containing compositions may be applied to soil, plant, and/or plant parts alone or in combination with additional components (such as chitin, chitosan, glucosamine, amino acids, and/or liquid fertilizer). In additional embodiments, the disclosed microbial consortia or compositions including microbes are used in methods of degrading biological materials, such as chitin-containing biological materials.

Abstract: The present disclosure relates to an adjuvant composition comprising lecithin; and, an organosilicon surfactant of formula (I): R1—Si(CH3)2—Z??(I) wherein: R1 is a branched monovalent hydrocarbon group of from 5 to 8 carbon atoms containing at least two methyl groups; Z is R2 or R3; R2 is CH2CH2CH2—OC2H4—O)a(C3H6O)b(C4H8O)c—R4 in which R4 is hydrogen, a linear or branched monovalent hydrocarbon group of from 1 to about 4 carbon atoms or an acyl group, subscript a is from 1 to about 20, subscript b is from 0 to about 19, subscript c is from 0 to about 19 and the sum of subscripts a, b and c is from 1 to about 20; and, R3 is —CH2CH2CH2—O—CH(OH)CH2—N+(CH3)2—R5 [X?] in which R5 is a linear or branched hydrocarbon group of from 1 to about 4 carbon atoms or an acetyl group and X? is a saturated or unsaturated carboxylate anion of from 2 to about 22 carbon atoms optionally containing 1 or 2 hydroxyl groups.

Abstract: The present invention provides a method of treating cancer in a patient including (1) a step of applying to a tumor a composition comprising (a) 0.01 to 3.5 weight percent of hydrogen peroxide in a final formulation and (b) hyaluronic acid or a salt of the hyaluronic acid, in which applying the composition is an intratumoral injection, and (2) a step of performing a radiotherapy treatment or an anti-cancer chemotherapy treatment at the same time as or after the step (1).

Abstract: This invention relates to a non-medical food additive that is an animal growth promoter containing 99% pure zeolite partially or totally exchanged with a Cm+ cation (in other words a synthetic zeolite) with the general formula I below: 1 m ? yC m + ? ( 1 - y ) ? 1 n ? M n + ? AlO 2 ? x ? SiO 2 in which x is greater than 1 and advantageously between 1 and 15; Mn+ represents an alkaline or alkaline earth exchangeable ion, advantageously Na+, K+, Ca2+ or Li+; n is between 1 and 2; y is the exchange rate and is between 0.001 and 1; Cm+ is a metallic cation chosen from among copper Cu2+, silver Ag+ or zinc Zn2+; m is between 1 and 2. It also relates to an additive premix and a supplemented food containing it and a method of improving the growth of animals.

Abstract: This invention relates to a method of treating a subject suffering from a condition characterized by damaged or degenerated soft tissue (such as, for example, intervertebral discs) by injecting swellable microgel particles to a location within the subject containing the damaged or degenerated soft tissue, after which said microgel particles covalently bind together in vivo to form a doubly cross-linked gel.

Abstract: An antimicrobial composition that includes a rhamnolipid and a cell membrane disruptor, wherein the cell membrane disruptor includes a carboxylic acid selected from the group consisting of caprylic acid, azelaic acid, caproic acid, malic acid, maleic acid, fumaric acid, succinic acid, glutaric acid, adipic acid, tartaric acid, and mixtures thereof, and wherein the cell membrane disruptor is present in the range of 0.01-10 wt % of the composition.

Abstract: This invention relates to microgel compositions, and in particular, to gel compositions formed by binding a plurality of individual microgel particles together. The present invention also relates to processes for the preparation of these compositions and their use for particular applications, especially medical applications such as the repair of damaged, degenerated or inappropriately formed load-bearing tissue (such as, for example, intervertebral discs).

Abstract: The present invention relates to a compound of formula (I) wherein: R1 is C1-C3alkoxy, C1-C2alkoxy-C1-C3alkoxy, C1-C2fluoroalkoxy, ethyl, n-propyl, n-butyl, cyclopropyl or ethynyl; R2 is hydrogen, ethyl, n-propyl, cyclopropyl, vinyl, ethynyl, C1-C3alkoxy, C1-C3fluoroalkyl, C1-C2fluoroalkoxy, C1-C2alkoxy-C1-C3alkoxy-, or C1fluoroalkoxy-C1-C3alkoxy-; provided that when R1 is ethyl, n-propyl, n-butyl, cyclopropyl or ethynyl, then R2 is hydrogen, ethyl, n-propyl, cyclopropyl, vinyl or ethynyl; and Y is O, S, S(O), S(O)2, N(C1-C2alkyl), N(C1-C2alkoxy), C(O), CR8R9 or —CR10R11CR12R13—; and G, R3, R4, R5 and R6 are as defined herein; wherein the compound of formula (I) is optionally present as an agrochemically acceptable salt thereof. These compounds are suitable for use as herbicides.

Abstract: A pharmaceutical formulation for use in a spinal fusion method, comprising a composition for forming a matrix, a kit comprising the composition, a pharmaceutical product obtainable from the pharmaceutical formulation, and an interbody spinal fusion cage containing the pharmaceutical formulation or the pharmaceutical product are described herein. The composition comprises at least a first matrix material precursor component and a second matrix material precursor component that are able to crosslink to form the matrix under appropriate conditions, a bioactive factor that is biologically active for stimulating bone formation between two vertebrae and for effecting or supporting spinal fusion. The bioactive factor is PTH, optionally a PTH fusion peptide. The bioactive factor is releasably incorporated in the matrix upon crosslinking of the matrix material precursor components.

Abstract: The present disclosure concerns embodiments of hard pullulan capsule shells and capsules comprising (I) moisture, (II) a mono-, di-, and oligosaccharides free pullulan and (III) a setting system. Also provided are an aqueous composition and a dip-molding manufacturing method for the manufacture of such shells and capsules.

Abstract: The present invention relates to a dosage regimen of an S1P receptor modulator or agonist in the course of the treatment of patients suffering from an inflammatory or autoimmune disorder, for example multiple sclerosis. Specifically, the present invention relates to testing a patient for a history of infection and vaccinating the patient prior to administration of fingolimod or a pharmaceutically acceptable salt thereof at a daily dosage of 0.5 mg.

Abstract: The present invention provides a novel radiosensitizer or anti-cancer chemotherapy sensitizer. In particular, the invention provides a radiosensitizer or anti-cancer chemotherapy sensitizer that can relieve the irritation of an affected area caused by hydrogen peroxide, is safe when injected into a human body, and can delay or reduce the degradation of hydrogen peroxide and thereby can efficiently exert a radiation sensitizing effect and an anti-cancer chemotherapy sensitizing effect. The radiosensitizer or anti-cancer chemotherapy sensitizer comprises a combination of (a) hydrogen peroxide and (b) hyaluronic acid or salt thereof.

Abstract: The current invention involves the surprising finding that when carboxylated particles, such as carboxylated polystyrene, PLGA, or diamond particles are administered to subjects, inflammatory immune responses are ameliorated. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same carboxylated particles.

Abstract: Disclosed are sublingual formulations of apomorphine, and methods of treating Parkinson's disease therewith. The sublingual formulations are films or strips having a first portion comprising apomorphine particles comprising an acid addition salt of apomorphine and a second portion comprising a pH neutralizing agent.

Abstract: A method of treatment and/or care of the skin includes administering a composition which includes a cosmetically or dermopharmaceutically effective quantity (between 0.000001% by weight and 5% by weight of the composition) of an exopolysaccharide produced by a strain of Halomonas eurihalina, or a ferment extract comprising the exopolysaccharide. The exopolysaccharide has a composition by weight of 0.5% to 45% of rhamnose, 0.1% to 25% of galactose, 0.5% to 30% of mannose, 50% to 95% for the sum of glucose and D-glucosamine, 0% to 10% of fucose and 0% to 12% of glucuronic acid, with the condition that the sum of the percentages does not exceed 100%.